Comprehensive B Cell Panel Components and Reference Ranges

| CD19 B Cells | |
|--------------------------|--|
| 0 up to 2 years | 10.2-18.5% of CD45 + Lymphocytes |
| 2 years up to 4 years | 16.5-25.8% of CD45 + Lymphocytes |
| 4 years up to 6 years | 13.4-21.1% of CD45 + Lymphocytes |
| 6 years up to 11 years | 9.8-17.7% of CD45 + Lymphocytes |
| 11 years up to 18 years | 10.2-15.4% of CD45 + Lymphocytes |
| 18 years and up | 1.4-15.0% of CD45 + Lymphocytes |
| | |
| NAÎVE (CD27-IGD+) | |
| 0 up to 2 years | 90.9-96.2% of total B cells |
| 2 years up to 4 years | 83.4-90.1% of total B cells |
| 4 years up to 6 years | 76.3-84.9% of total B cells |
| 6 years up to 11 years | 69.4-80.4% of total B cells |
| 11 years up to 18 years | 75.2-86.7% of total B cells |
| 18 years and up | 45.1-91.4% of total B cells |
| Total Non-Switch (CD27- | HGD+) |
| 0 up to 2 years | 1.6-4.1% of total B cells |
| 2 years up to 4 years | 4.2-6.9% of total B cells |
| 4 years up to 6 years | 4.1-9.0% of total B cells |
| 6 years up to 11 years | 7.5-12.4% of total B cells |
| 11 years up to 18 years | 4.6-10.2% of total B cells |
| 18 years and up | 0.0-25.0% of total B cells |
| • | |
| Total Class Switched (CI | 027+IGD-) |
| 0 up to 2 years | 0.1-1.9% of total B cells |
| 2 years up to 4 years | 1.5-4.1% of total B cells |
| 4 years up to 6 years | 3.3-7.4% of total B cells |
| 6 years up to 11 years | 5.2-12.1% of total B cells |
| 11 years up to 18 years | 3.3-9.6% of total B cells |
| 18 years and up | 1.1-30.5% of total B cells |
| CD21Lo B Cells (CD21L0 | OCD381 O/ |
| 0 up to 2 years | 0.3-4.0% of total B cells |
| 2 years up to 4 years | 1.8-3.6% of total B cells |
| 4 years up to 6 years | 1.8-5.2% of total B cells |
| 6 years up to 11 years | 0.9-3.5% of total B cells |
| 11 years up to 18 years | 0.9-3.3% of total B cells |
| 18 years and up | 0.0-8.4% of total B cells |
| | |
| Transitional (IGM+CD38- | |
| 0 up to 2 years | 8.3-15.8% of total B cells |
| 2 years up to 4 years | 5.1-10.7% of total B cells |
| 4 years up to 6 years | 5.4-9.2% of total B cells |
| 6 years up to 11 years | 4.5-9.2% of total B cells |
| 11 years up to 18 years | 3.9-7.8% of total B cells |
| 18 years and up | 0.0-8.3% of total B cells |
| Plasmablasts (IGM-CD38 | 3++) |
| 0 up to 6 years | 0.2-5.5% of total B cells |
| 6 years up to 11 years | 0.5-5.3% of total B cells |
| 11 years up to 18 years | 0.6-6.5% of total B cells |
| 18 years and up | 0.0-3.0% of total B cells |
| IOM Only M | · IOM· · |
| IGM Only Memory (CD27 | |
| | No reference ranges for these populations, for informational purposes only |
| 0 up to 18 years | TOT ITTOTTIALIOTIAL DULDUSES UTILV |
| 18 years and up | 0.0-33.0% of CD27 + B cells |
| | |
| | 0.0-33.0% of CD27 + B cells |
| 18 years and up | 0.0-33.0% of CD27 + B cells 7+IGM+IGD+) No reference ranges for these populations, |
| 18 years and up | 0.0-33.0% of CD27 + B cells 7+IGM+IGD+) |

| IGM-IGD-Memory (CD27+IGD-IGM-) | | |
|--------------------------------|--|--|
| 0 up to 18 years | No reference range for these populations, for informational purposes only. | |
| 18 years and up | 14.1-76.3% of CD27 + B cells | |
| | | |
| Plasmablasts (CD27+ | ·CD38+++IGM-) | |
| 0 up to 18 years | No reference range for these populations, for informational purposes only. | |
| 18 years and up | 0.0-9.6% of CD27 + B cells | |